Obesity represents a well-known risk factor for renal cell carcinoma development. Several studies evaluated the relationship between obesity and outcome in patients with non-metastatic and metastatic renal cell carcinoma using different parameters such as BMI, visceral fat area and s.c. fat area. These studies suggest that obesity is associated with a better prognosis in renal cell carcinoma patients. This phenomenon is called obesity paradox and it was found in other diseases in which obesity rep resents an established risk factor such as heart failure, diabetes, atrial fibrillation, hypertension and coronary heart disease. The purpose of this review is to analyze the mec hanisms by which obesity increases the risk of renal cell carcinoma development, to describe the evidence available to date about the link obesity-outcome and to evaluate the mech anisms to explain this apparently paradoxical relationship.

Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC

Turco F.
First
;
Di Stefano R. F.;Samuelly A.;Bungaro M.;Audisio M.;Pisano C.;Di Maio M.;Scagliotti G. V.;Buttigliero C.
Last
2021-01-01

Abstract

Obesity represents a well-known risk factor for renal cell carcinoma development. Several studies evaluated the relationship between obesity and outcome in patients with non-metastatic and metastatic renal cell carcinoma using different parameters such as BMI, visceral fat area and s.c. fat area. These studies suggest that obesity is associated with a better prognosis in renal cell carcinoma patients. This phenomenon is called obesity paradox and it was found in other diseases in which obesity rep resents an established risk factor such as heart failure, diabetes, atrial fibrillation, hypertension and coronary heart disease. The purpose of this review is to analyze the mec hanisms by which obesity increases the risk of renal cell carcinoma development, to describe the evidence available to date about the link obesity-outcome and to evaluate the mech anisms to explain this apparently paradoxical relationship.
2021
28
7
207
216
Immune checkpoint inhibitors; Obesity; Obesity paradox; Renal cell carcinoma; Tyrosine kinase inhibitors
Turco F.; Tucci M.; Di Stefano R.F.; Samuelly A.; Bungaro M.; Audisio M.; Pisano C.; Di Maio M.; Scagliotti G.V.; Buttigliero C.
File in questo prodotto:
File Dimensione Formato  
review obesità-tumore renale FT_CB_MT.docx

Accesso riservato

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 27.64 kB
Formato Microsoft Word XML
27.64 kB Microsoft Word XML   Visualizza/Apri   Richiedi una copia
review obesità-tumore renale FT_CB_MT.pdf

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 163.48 kB
Formato Adobe PDF
163.48 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1793553
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact